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Percutaneous coronary intervention (PCI) has evolved from
a technique initially confined to the treatment of simple
short lesions in large non-calcified vessels to a technique
that is applicable to a wide range of complex lesions,
including thrombotic, calcified, or ostial lesions; bifurcation
lesions; chronic total occlusions; long lesions in small vessels
with diffuse disease; and even left main stem disease. The
type of patient treated by PCI also has dramatically
changed. In the early days, only stable symptomatic patients
were referred for PCI; nowadays, PCI has a major role in
treating patients with either unstable angina or acute myo-
cardial infarction (MI). Furthermore, PCI with stent im-
plantation frequently is performed in asymptomatic patients
after acute MI based on evidence that an open artery has
favorable effects on left ventricular (LV) remodeling and
may improve prognosis.
See page 1722
The effectiveness of PCI in relieving angina and the
relative safety, simplicity, and patient friendliness of the
technique have increased its popularity to such an extent
that, nowadays, in the U.S. and in most European countries,
more patients are referred for PCI than for coronary artery
bypass grafting.
Overall, the procedure is safe, but as a result of the
expanding indications and of the increasing number of
centers performing PCI, the risk of major irreversible
procedural complications, including death, MI, stroke, and
need for urgent bailout bypass surgery, may vary widely
depending on the clinical setting, the lesion complexity, and
probably on the experience of the operator.
The benefits of the procedure in patients referred for PCI
should be weighed against the risks involved, taking into
account alternative treatment strategies. This is particularly
the case in patients who do not have invalidating symptoms.
Always keep in mind: “do not harm your patient.” The
treatment strategy with the optimal risk-benefit ratio should
be chosen for every patient. To provide a rational framework
for assessing risk, several risk scores have been proposed for
predicting the occurrence of major procedural complications
during PCI (1–8). Usually, these scores classify patients into
low-, intermediate-, and high-risk groups. These scores
help to assess the potential for benefit against the potential
for harm and can provide an objective basis for discussion
with patients and their families. Cardiologists and patients
can then jointly make an informed decision regarding the
most suitable treatment option: continued optimal medical
treatment, coronary artery bypass grafting, or PCI.
In addition, these scores allow a fairer comparison of the
performance of different institutions or operators than crude
complication rates. Thus, they may provide data that are
helpful in disclosing differences in performance of low- and
high-volume institutions or operators. Finally, institutions
or operators that accept a high-risk patient to undergo PCI
should have back-up facilities such as intra-aortic balloon
pumps, LV assist devices, and on-site surgical stand-by.
RISK SCORE FOR PCI
A risk score for PCI should fulfill the following criteria:
1. It should be derived from simple and easily obtainable
variables that are available before the procedure.
2. It should predict not only mortality but all major
procedural complications, including mortality, MI,
stroke, and the need for urgent bypass surgery.
3. It should be validated internally and externally.
4. It should reflect modern PCI practice, which currently
includes stent implantation, GP-IIb/IIIa blockers, and
post-stent thienopyridine administration.
The Mayo Clinic risk score model for complications after
PCI is published in this issue of the Journal (9). The model
was first developed from a learning set of 5,463 procedures
performed between January 1996 and December 1999 and
was internally tested in a validation set of 1,781 PCI
procedures performed in the year 2000 (10). Subsequently,
the investigators validated their score in an external
validation set using 3,264 patients undergoing PCI from
the National Heart, Lung and Blood Institute Dynamic
Registry during two enrollment periods (July 1997 to
February 1998 and February to June 1999) with excellent
results. Thus, the Mayo Clinic risk score is the first
score that appears to fulfill all the above criteria. The risk
*Editorials published in the Journal of the American College of Cardiology reflect the
views of the authors and do not necessarily represent the views of JACC or the
American College of Cardiology.
From the Erasmus Medical Center, Rotterdam, The Netherlands.




Serum creatinine 265 ml/l (3.5 mg/dl) (or history of chronic or
end-stage renal disease)
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score has eight simple clinical and angiographic variables
(Table 1). Each of the seven binary variables was assigned a
predetermined integer score proportional to its effects; age,
the only continuous variable, was assigned an integer score
on a continuous scale. Adding the scores assigned to each
variable gives an overall score that allows the classification of
patients into five risk categories ranging from very low to
very high risk, with each category having its own predicted
major procedural complication rate (Fig. 1).
The risk score was also tested in various clinical low- and
high-risk subgroups and by and large the observed and
predicted complication rates were consistent among groups.
No risk score is perfect, and this score does not take into
account the difference in outcome when PCI is performed
in a low-volume center.
Yet, the Mayo risk score is the best score available and
should be used for patient risk stratification at the time of
initial presentation. The score provides factual information
that is extremely helpful when discussing the procedure with
the patient, his or her family, or his or her referring
physician. Very high-risk PCI procedures are of course
sometimes inevitable because of the inherent risks of the
underlying disease. However, previous knowledge of a (very)
high risk of major procedural complications should alert the
investigator and should trigger measures to reduce the risk
to the extent that this is possible. Selection of experienced
operators, standby or preoperative insertion of an intra-
aortic balloon pump, the use of a LV assist device where
available, and assurance of immediate surgical backup are
some potential safeguards. The safety of the patient is the
pre-eminent concern, and efforts are continuing to develop
even safer PCI devices and devices that improve procedural
safety. For instance, simple effective distal protection devices
to prevent distal embolization or LV assist devices that
could be easily and quickly inserted in case of emergency
would be invaluable in this setting. Intelligent use of the
Mayo Clinic risk score should make percutaneous interven-
tion procedures safer: forewarned is forearmed.
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Figure 1. Mayo Clinic risk score. MV  mitral valve; NYHA  New York Heart Association.
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